Growing Human Organs Inside Pigs Could Save Lives, But the U.S. Won't Fund the Research

Growing Human Organs Inside Pigs Could Save Lives, But the U.S. Won't Fund the Research

Pigs in a barn.

(© caspernhdk/Adobe)


Keep Reading Keep Reading
Alejandro De Los Angeles
Alejandro De Los Angeles is a visiting researcher at Yale University. He has done research at several leading institutions, including Stanford, Yale, Columbia, and the Genome Institute of Singapore. A Connecticut native, he has published over 25 papers on stem cells and human-animal interspecies chimeras. Alejandro’s research has focused on identifying stem cells capable of forming interspecies chimeras. Recently, Alejandro discovered a new type of monkey pluripotent stem cell that might possess the capability of forming interspecies chimeras. He also showed that the same method works in human stem cells. De Los Angeles’s work has appeared in major scientific journals, including the top journal Nature. In addition to his scientific work in the laboratory, he also collaborates with bioethicists and recently co-edited a book on chimera research and ethics titled, “Chimera Research,” published by Springer Nature.
Hidden figures: Five black women that changed science forever

Dr. May Edward Chinn, Kizzmekia Corbett, PhD., and Alice Ball, among others, have been behind some of the most important scientific work of the last century.


Keep Reading Keep Reading
Sarah Watts

Sarah Watts is a health and science writer based in Chicago.

natural killer cell
NIAID, CC BY 2.0 <https://creativecommons.org/licenses/by/2.0>, via Wikimedia Commons

On today’s episode of Making Sense of Science, I’m honored to be joined by Dr. Paul Song, a physician, oncologist, progressive activist and biotech chief medical officer. Through his company, NKGen Biotech, Dr. Song is leveraging the power of patients’ own immune systems by supercharging the body’s natural killer cells to make new treatments for Alzheimer’s and cancer.

Whereas other treatments for Alzheimer’s focus directly on reducing the build-up of proteins in the brain such as amyloid and tau in patients will mild cognitive impairment, NKGen is seeking to help patients that much of the rest of the medical community has written off as hopeless cases, those with late stage Alzheimer’s. And in small studies, NKGen has shown remarkable results, even improvement in the symptoms of people with these very progressed forms of Alzheimer’s, above and beyond slowing down the disease.

Keep Reading Keep Reading
Matt Fuchs
Matt Fuchs is the host of the Making Sense of Science podcast and served previously as the editor-in-chief of Leaps.org. He writes as a contributor to the Washington Post, and his articles have also appeared in the New York Times, WIRED, Nautilus Magazine, Fortune Magazine and TIME Magazine. Follow him @fuchswriter.